Philochem AG Licenses OncoACP3 Rights to RayzeBio in $1.35bn Deal

Reuters

06-11

Philochem AG Licenses OncoACP3 Rights to RayzeBio in $1.35bn Deal

Philochem AG, a wholly-owned subsidiary of the Philogen Group, has announced a definitive agreement with RayzeBio, a subsidiary of Bristol-Myers Squibb Company, to license the worldwide rights for OncoACP3. This novel radiopharmaceutical therapeutic and diagnostic agent targets prostate cancer and is valued at up to $1.35 billion, including a $350 million up-front payment, and up to $1 billion in development, regulatory, and commercial milestones. Additionally, Philochem will receive mid-single to low double-digit royalties on global net sales of both therapeutic and diagnostic agents of OncoACP3. This collaboration reinforces Philochem's commitment to advancing scientific innovation into clinical solutions, aiming to make OncoACP3 therapies accessible to patients in need.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Philogen S.p.A. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001101940-en) on June 10, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2542328761"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542328761\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2542328761?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-11 05:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542328761","market":"us","top_or_hot":-1,"title":"Philochem AG Licenses OncoACP3 Rights to RayzeBio in $1.35bn Deal","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Philochem AG Licenses OncoACP3 Rights to RayzeBio in $1.35bn Deal\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Philochem AG, a wholly-owned subsidiary of the Philogen Group, has announced a definitive agreement with RayzeBio, a subsidiary of Bristol-Myers Squibb Company, to license the worldwide rights for OncoACP3. This novel radiopharmaceutical therapeutic and diagnostic agent targets prostate cancer and is valued at up to $1.35 billion, including a $350 million up-front payment, and up to $1 billion in development, regulatory, and commercial milestones. Additionally, Philochem will receive mid-single to low double-digit royalties on global net sales of both therapeutic and diagnostic agents of OncoACP3. This collaboration reinforces Philochem's commitment to advancing scientific innovation into clinical solutions, aiming to make OncoACP3 therapies accessible to patients in need.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Philogen S.p.A. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001101940-en) on June 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Philochem AG Licenses OncoACP3 Rights to RayzeBio in $1.35bn Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPhilochem AG Licenses OncoACP3 Rights to RayzeBio in $1.35bn Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-11 05:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Philochem AG Licenses OncoACP3 Rights to RayzeBio in $1.35bn Deal\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Philochem AG, a wholly-owned subsidiary of the Philogen Group, has announced a definitive agreement with RayzeBio, a subsidiary of Bristol-Myers Squibb Company, to license the worldwide rights for OncoACP3. This novel radiopharmaceutical therapeutic and diagnostic agent targets prostate cancer and is valued at up to $1.35 billion, including a $350 million up-front payment, and up to $1 billion in development, regulatory, and commercial milestones. Additionally, Philochem will receive mid-single to low double-digit royalties on global net sales of both therapeutic and diagnostic agents of OncoACP3. This collaboration reinforces Philochem's commitment to advancing scientific innovation into clinical solutions, aiming to make OncoACP3 therapies accessible to patients in need.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Philogen S.p.A. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001101940-en) on June 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1868836591.USD","symbol_name":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250610:nNDL9MSMQh:1","article_id":"2542328761","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542328761","pubTimestamp":1749592530,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Philogen S.p.A. published the original content used to generate this news brief via GlobeNewswire  on June 10, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","BMY":"施贵宝","BK4532":"文艺复兴科技持仓","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","BK4007":"制药","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","BK4559":"巴菲特持仓","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","NDAQ":"纳斯达克OMX交易所","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC"},"translate_title":"Philochem AG以13.5亿美元的交易向RayzeBio授予OncoACP3权利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMY":0.9,"NDAQ":0.9},"content_text":"Philochem AG Licenses OncoACP3 Rights to RayzeBio in $1.35bn Deal\n    \n\n        Philochem AG, a wholly-owned subsidiary of the Philogen Group, has announced a definitive agreement with RayzeBio, a subsidiary of Bristol-Myers Squibb Company, to license the worldwide rights for OncoACP3. This novel radiopharmaceutical therapeutic and diagnostic agent targets prostate cancer and is valued at up to $1.35 billion, including a $350 million up-front payment, and up to $1 billion in development, regulatory, and commercial milestones. Additionally, Philochem will receive mid-single to low double-digit royalties on global net sales of both therapeutic and diagnostic agents of OncoACP3. This collaboration reinforces Philochem's commitment to advancing scientific innovation into clinical solutions, aiming to make OncoACP3 therapies accessible to patients in need.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Philogen S.p.A. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001101940-en) on June 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}